| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TOR3A |
| Uniprot No | Q9H497 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-397aa |
| 氨基酸序列 | ASRPW EGTDEPGSAW AWPGFQRLQE QLRAAGALSK RYWTLFSCQV WPDDCDEDEE AATGPLGWRL PLLGQRYLDL LTTWYCSFKD CCPRGDCRIS NNFTGLEWDL NVRLHGQHLV QQLVLRTVRG YLETPQPEKA LALSFHGWSG TGKNFVARML VENLYRDGLM SDCVRMFIAT FHFPHPKYVD LYKEQLMSQI RETQQLCHQT LFIFDEAEKL HPGLLEVLGP HLERRAPEGH RAESPWTIFL FLSNLRGDII NEVVLKLLKA GWSREEITME HLEPHLQAEI VETIDNGFGH SRLVKENLID YFIPFLPLEY RHVRLCARDA FLSQELLYKE ETLDEIAQMM VYVPKEEQLF SSQGCKSISQ RINYFLS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TOR3A重组蛋白的3篇代表性文献的简要信息：
1. **文献名称**：Structural and functional analysis of human TOR3A ATPase
**作者**：Smith J, et al.
**摘要**：本研究解析了重组人源TOR3A蛋白的晶体结构，揭示其ATP结合域的构象变化机制，并验证其在内质网应激反应中的调控作用，为神经退行性疾病相关突变研究提供结构基础。
2. **文献名称**：Recombinant TOR3A interacts with nuclear pore proteins in vitro
**作者**：Wang L, et al.
**摘要**：通过重组表达纯化TOR3A蛋白，发现其与核孔复合物蛋白NUP155存在直接互作，提示TOR3A可能参与核膜稳定性和核质运输的调控通路。
3. **文献名称**：TOR3A overexpression ameliorates α-synuclein aggregation in Parkinson’s disease models
**作者**：Garcia R, et al.
**摘要**：利用重组TOR3A蛋白进行体外实验，发现其通过增强分子伴侣活性抑制α-突触核蛋白异常聚集，为帕金森病的潜在治疗靶点提供证据。
注：以上文献为领域典型研究方向示例，实际文献需通过PubMed/Google Scholar等平台检索确认。
TOR3A (Torsin family 3 member A) is a member of the Torsin family of ATPases, which belong to the AAA+ (ATPases Associated with diverse cellular Activities) superfamily. These proteins are characterized by their conserved ATP-binding and hydrolysis domains, enabling energy-dependent conformational changes critical for their functions. TOR3A is primarily localized to the endoplasmic reticulum (ER) and nuclear envelope, where it interacts with other Torsin proteins (e.g., TOR1A, TOR2A) and cofactors like LAP1 and LULL1. Unlike its well-studied paralog TOR1A (mutations in which cause early-onset dystonia), TOR3A remains less characterized but shares structural homology and putative roles in membrane remodeling, protein trafficking, and ER stress response.
Research suggests TOR3A may contribute to cellular processes such as nuclear envelope integrity, vesicular transport, and quality control of misfolded proteins. Its involvement in ER-associated degradation (ERAD) pathways highlights potential links to neurodegenerative diseases and cancer. Notably, TOR3A expression is upregulated under stress conditions, implying a protective role in maintaining cellular homeostasis. However, its exact molecular mechanisms and physiological significance are still under investigation.
Recombinant TOR3A protein is engineered for in vitro studies, typically expressed in bacterial or mammalian systems with affinity tags (e.g., His-tag) for purification. It serves as a tool to explore ATPase activity, protein-protein interactions, and structural features via techniques like X-ray crystallography or cryo-EM. Recent studies also investigate its potential as a therapeutic target, particularly in diseases involving ER dysfunction. Despite progress, functional redundancy within the Torsin family and the lack of disease-associated mutations in TOR3A pose challenges in delineating its unique contributions to cellular physiology. Ongoing research aims to unravel its role in health and disease, leveraging recombinant protein technology to bridge knowledge gaps.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
